Clinical Trial Update: Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC) [Phase 2]

View source ↗

Summary

Phase 2 trial of MCS110 combined with carboplatin and gemcitabine in advanced triple-negative breast cancer with high tumor-associated macrophages completed; re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Gemcitabine (Gemcitabine)
• MCS110

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Advanced Triple Negative Breast Cancer (TNBC) With High TAMs | Phase 2 | Status: COMPLETED | Results posted: 2021-06-21